latest update:
[TrialBase DB]

trial summary · NCT07851259

A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Phase II, Randomized, Double-Masked, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of RO7965032 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Trial record from the TrialBase DB dataset, status RECRUITING, condition Geographic Atrophy Secondary to Age-Related Macular Degeneration, sponsored by Genentech, Inc.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07851259phase PHASE2enrollment 321start 2027-01-08

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Source record: https://clinicaltrials.gov/study/NCT07851259

Facts

registry idNCT07851259
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionGeographic Atrophy Secondary to Age-Related Macular Degeneration
sponsorGenentech, Inc.
sponsor classINDUSTRY
enrollment321
start date2027-01-08
primary completion2030-08-21
completion2030-08-21
results postednot reported

Conditions

  • Geographic Atrophy Secondary to Age-Related Macular Degeneration

Interventions

  • RO7965032
  • Placebo

Countries

  • United States

Intervention types: DRUG

Work with this record